when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Obesity · news · pharmadog

← back to Obesity

News mentioning Obesity

367 stories

May 1, 26STAT+: Up and down the ladder: The latest comings and goingsstat

May 1, 26STAT+: Axsome wins FDA nod for Alzheimer’s agitationstat

May 1, 26STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and morestat

May 1, 26STAT+: Her daughter Mila got a bespoke medicine. Now she’s starting a new biotech to make morestat

Apr 30, 26Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstoodstat

Apr 30, 26STAT+: Katherine Szarama named acting director of FDA’s vaccines and biologics centerstat

Apr 30, 26Court dismisses part of Lilly lawsuit against Empower, some claims can proceedendpoints

Apr 30, 26STAT+: As artificial intelligence shows off diagnostic chops, scientists reckon with the way forwardstat

Apr 30, 26STAT+: FDA wants to exclude weight loss drugs from a compounding liststat

Apr 30, 26STAT+: Five-way obesity drug is super effective — in micestat

Apr 30, 26STAT+: DOJ, Elevance spar over access to top exec in Medicare Advantage fraud casestat

Apr 30, 26Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launchbiopharma dive

Apr 30, 26Smog from wildfires increasingly harmful, data showstat

Apr 30, 26Updated: Early sales of Lilly’s obesity pill appear to trail Novo’sendpoints

Apr 30, 26STAT+: New obesity tool aims to predict risk of 18 serious complicationsstat

Apr 29, 26STAT+: A patent win for Pfizer and BridgeBiostat

Apr 28, 26STAT+: FDA launches effort to speed up clinical trials, using AIstat

Apr 28, 26Fauci adviser David Morens indicted on charges of concealing emails, avoiding records requestsstat

Apr 28, 26Boehringer dual-acting obesity shot hits mark in Phase 3 trialbiopharma dive

Apr 28, 26STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data neededstat

Apr 28, 26STAT+: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and morestat

Apr 28, 26Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.biopharma dive

Apr 28, 26STAT+: Eli Lilly enlists AI startup for next-generation gene editorsstat

Apr 28, 26Boehringer, Zealand’s obesity shot looks as good as Novo's Wegovy, but weaker than Lilly's Zepboundendpoints

Apr 27, 26Lilly to buy startup Ajax in bid for a better JAK drugbiopharma dive

Apr 27, 26STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and morestat

Apr 27, 26What’s the true risk for eating disorders with GLP-1s?stat

Apr 27, 26Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitorendpoints

Apr 25, 26Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugsstat

Apr 24, 26STAT+: Up and down the ladder: The latest comings and goingsstat

← prevpage 12 of 13next →